This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks Industry Outlook Highlights: Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals
by Zacks Equity Research
Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals are highlighted in this Industry Outlook article.
Will the Rally of These 5 Big Drugmakers Continue in 2022?
by Zacks Equity Research
Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.
The Zacks Analyst Blog Highlights AbbVie, The Boeing Company, Infosys Limited, Ford Motor Company and Public Storage
by Zacks Equity Research
The Zacks Analyst Blog Highlights AbbVie, The Boeing Company, Infosys Limited, Ford Motor Company and Public Storage are included in this analyst blog.
Top Analyst Reports for AbbVie, Boeing & Infosys
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), The Boeing Company (BA), and Infosys Limited (INFY).
Amgen (AMGN) Provides Strong Long-Term Outlook, Shares Up
by Zacks Equity Research
Amgen (AMGN) outlines a strategy to grow its business through the end of this decade on the back of strong demand for existing products and potential of novel pipeline candidates targeting diverse indications.
The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer
by Zacks Equity Research
AbbVie, Merck, Eli Lilly, Novartis and Pfizer are included in this analyst blog.
Viatris (VTRS) Gets FDA Nod for Generic Drug in Dry Eye Disease
by Zacks Equity Research
Viatris' (VTRS) subsidiary is the first to receive approval from the FDA to market a generic version of AbbVie's Restasis for the treatment of dry eye disease.
Pharma Stock Roundup: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.
AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.
AbbVie (ABBV) Tops Q4 Earnings Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 0.61% and 0.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO
by Indrajit Bandyopadhyay
Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.
Why AbbVie (ABBV) Might Surprise This Earnings Season
by Zacks Equity Research
AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Buyers Come In With A Penchant For Growth After Short Market Correction
by Daniel Laboe
This week's riveting earnings line-up promises to be chalked full of enlightening quarterly reports from leading corporations across sectors
Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.
Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema
by Zacks Equity Research
While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.
AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery
by Zacks Equity Research
AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.
Zacks Investment Ideas feature highlights: Bank of America, AbbVie, and Microsoft
by Zacks Equity Research
Bank of America, AbbVie, and Microsoft are highlighted in this Investment Ideas article.
Value, Growth, or Momentum: What Kind of Investor are You?
by Madeleine Johnson
No matter what strategy you decide is best in 2022, always remember that investing is a personal journey. Your life, and where you see yourself in 10, 20, 30 years, should be the driving force behind your investing decisions and strategies.
Is a Beat Likely for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) fourth-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics. Investors are likely to focus on any update related to the guidance for 2022.
Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.
Pharma Stock Roundup: J&J Q4 Earnings, FDA's Rejection of PFE, MRK Pipeline Drugs
by Kinjel Shah
J&J (JNJ) reports mixed fourth-quarter results. FDA issues CRL to Merck (MRK) and Pfizer's (PFE) pipeline candidates. FDA approves AbbVie's (ABBV) Skyrizi for a second indication.
The Zacks Analyst Blog Highlights: AbbVie, Edwards Lifesciences and Johnson Controls International
by Zacks Equity Research
AbbVie, Edwards Lifesciences and Johnson Controls International are included in this analyst blog.
2 Stocks to Buy During Market Turbulence Before Earnings
by Benjamin Rains
Diving into two strong stocks that also pay a dividend that investors might want to consider buying heading into earnings...
Should Value Investors Pick AbbVie (ABBV) At Present?
by Vedika Agarwal
Is AbbVie (ABBV) a great pick from the value investor's perspective right now? Read on to know more.
Top Analyst Reports for AbbVie, Edwards Lifesciences & Johnson Controls
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Edwards Lifesciences Corporation (EW), and Johnson Controls International plc (JCI).